RU2762562C9 - ПРОИЗВОДНОЕ п-ФЕНИЛЕНДИАМИНА КАК РЕГУЛЯТОР КАЛИЕВЫХ КАНАЛОВ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И МЕДИЦИНСКОГО ПРИМЕНЕНИЯ - Google Patents
ПРОИЗВОДНОЕ п-ФЕНИЛЕНДИАМИНА КАК РЕГУЛЯТОР КАЛИЕВЫХ КАНАЛОВ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И МЕДИЦИНСКОГО ПРИМЕНЕНИЯ Download PDFInfo
- Publication number
- RU2762562C9 RU2762562C9 RU2020141928A RU2020141928A RU2762562C9 RU 2762562 C9 RU2762562 C9 RU 2762562C9 RU 2020141928 A RU2020141928 A RU 2020141928A RU 2020141928 A RU2020141928 A RU 2020141928A RU 2762562 C9 RU2762562 C9 RU 2762562C9
- Authority
- RU
- Russia
- Prior art keywords
- compound
- mmol
- ring
- solution
- mixture
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
- C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D267/02—Seven-membered rings
- C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810493023 | 2018-05-22 | ||
CN201810493023.9 | 2018-05-22 | ||
PCT/CN2019/088012 WO2019223732A1 (zh) | 2018-05-22 | 2019-05-22 | 作为钾通道调节剂的对二氨基苯衍生物、其制备方法及其在医药上的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2762562C1 RU2762562C1 (ru) | 2021-12-21 |
RU2762562C9 true RU2762562C9 (ru) | 2022-04-20 |
Family
ID=68617196
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2020141928A RU2762562C9 (ru) | 2018-05-22 | 2019-05-22 | ПРОИЗВОДНОЕ п-ФЕНИЛЕНДИАМИНА КАК РЕГУЛЯТОР КАЛИЕВЫХ КАНАЛОВ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И МЕДИЦИНСКОГО ПРИМЕНЕНИЯ |
Country Status (14)
Country | Link |
---|---|
US (2) | US11365181B2 (hr) |
EP (1) | EP3798220B1 (hr) |
JP (1) | JP7294681B2 (hr) |
KR (1) | KR102599761B1 (hr) |
CN (2) | CN110511220B (hr) |
AU (1) | AU2019272383B2 (hr) |
BR (1) | BR112020023861A2 (hr) |
CA (1) | CA3101226C (hr) |
ES (1) | ES2963614T3 (hr) |
HR (1) | HRP20231475T1 (hr) |
PL (1) | PL3798220T3 (hr) |
RS (1) | RS64710B1 (hr) |
RU (1) | RU2762562C9 (hr) |
WO (1) | WO2019223732A1 (hr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114057641A (zh) * | 2020-08-07 | 2022-02-18 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的四氢异喹啉类化合物及其制备和应用 |
CN115724799A (zh) * | 2021-08-26 | 2023-03-03 | 杭州和正医药有限公司 | 一种钾通道调节剂、组合物及应用 |
CN113698345B (zh) * | 2021-10-27 | 2022-02-01 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的化合物及其制备和应用 |
CN116535353A (zh) * | 2022-01-25 | 2023-08-04 | 上海挚盟医药科技有限公司 | 作为钾通道调节剂的酰胺类化合物及其制备和应用 |
WO2024067819A1 (zh) * | 2022-09-30 | 2024-04-04 | 上海翰森生物医药科技有限公司 | 含哌啶多环类衍生物调节剂、其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2014328C1 (ru) * | 1987-04-01 | 1994-06-15 | Жансен Фармасетика Н.В. | Способ получения производных n-арилпиперазиналканамида |
WO2004058739A1 (en) * | 2002-12-27 | 2004-07-15 | H. Lundbeck A/S | 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system |
WO2006029623A1 (en) * | 2004-09-13 | 2006-03-23 | H. Lundbeck A/S | Substituted aniline derivatives |
WO2009015667A1 (en) * | 2007-08-01 | 2009-02-05 | H. Lundbeck A/S | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090079191A (ko) * | 2006-08-23 | 2009-07-21 | 밸리언트 파마슈티컬즈 인터내셔널 | 칼륨 채널 조절제로서 4-(n-아자사이클로알킬) 아닐리드의 유도체 |
CN101578259A (zh) | 2006-11-28 | 2009-11-11 | 威朗国际制药公司 | 作为钾通道调节剂的1,4-二氨基双环瑞替加滨类似物 |
US8367684B2 (en) * | 2007-06-13 | 2013-02-05 | Valeant Pharmaceuticals International | Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators |
US8563566B2 (en) * | 2007-08-01 | 2013-10-22 | Valeant Pharmaceuticals International | Naphthyridine derivatives as potassium channel modulators |
WO2010094645A1 (en) * | 2009-02-17 | 2010-08-26 | Neurosearch A/S | Substituted pyridine derivatives and their medical use |
CN108250128A (zh) * | 2012-09-27 | 2018-07-06 | 江苏先声药业有限公司 | 作为钾通道调节剂的化合物 |
-
2019
- 2019-05-21 CN CN201910425178.3A patent/CN110511220B/zh active Active
- 2019-05-22 BR BR112020023861-9A patent/BR112020023861A2/pt unknown
- 2019-05-22 RS RS20230957A patent/RS64710B1/sr unknown
- 2019-05-22 CA CA3101226A patent/CA3101226C/en active Active
- 2019-05-22 PL PL19808475.8T patent/PL3798220T3/pl unknown
- 2019-05-22 ES ES19808475T patent/ES2963614T3/es active Active
- 2019-05-22 JP JP2020565315A patent/JP7294681B2/ja active Active
- 2019-05-22 US US17/057,457 patent/US11365181B2/en active Active
- 2019-05-22 HR HRP20231475TT patent/HRP20231475T1/hr unknown
- 2019-05-22 CN CN201980032993.1A patent/CN112119079A/zh active Pending
- 2019-05-22 WO PCT/CN2019/088012 patent/WO2019223732A1/zh active Application Filing
- 2019-05-22 KR KR1020207036438A patent/KR102599761B1/ko active IP Right Grant
- 2019-05-22 AU AU2019272383A patent/AU2019272383B2/en active Active
- 2019-05-22 RU RU2020141928A patent/RU2762562C9/ru active
- 2019-05-22 EP EP19808475.8A patent/EP3798220B1/en active Active
-
2022
- 2022-04-07 US US17/715,935 patent/US20220227721A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2014328C1 (ru) * | 1987-04-01 | 1994-06-15 | Жансен Фармасетика Н.В. | Способ получения производных n-арилпиперазиналканамида |
WO2004058739A1 (en) * | 2002-12-27 | 2004-07-15 | H. Lundbeck A/S | 1,2,4-triaminobenzene derivatives useful for treating disorders of the central nervous system |
WO2006029623A1 (en) * | 2004-09-13 | 2006-03-23 | H. Lundbeck A/S | Substituted aniline derivatives |
WO2009015667A1 (en) * | 2007-08-01 | 2009-02-05 | H. Lundbeck A/S | Use of kncq potassium channel openers for reducing symptoms of or treating disorders or conditions wherein the dopaminergic system is disrupted |
Non-Patent Citations (1)
Title |
---|
YANG S. et al., Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy, Bioorganic & Medicinal Chemistry Letters, 08.05.2018, vol. 28, no. 17, p. 3004-3008. * |
Also Published As
Publication number | Publication date |
---|---|
PL3798220T3 (pl) | 2024-02-26 |
CA3101226A1 (en) | 2019-11-28 |
CN110511220B (zh) | 2022-04-01 |
KR20210011968A (ko) | 2021-02-02 |
EP3798220B1 (en) | 2023-08-23 |
US20210163429A1 (en) | 2021-06-03 |
EP3798220C0 (en) | 2023-08-23 |
AU2019272383A1 (en) | 2021-01-14 |
US20220227721A1 (en) | 2022-07-21 |
CN112119079A (zh) | 2020-12-22 |
BR112020023861A2 (pt) | 2021-04-13 |
ES2963614T3 (es) | 2024-04-01 |
CN110511220A (zh) | 2019-11-29 |
RS64710B1 (sr) | 2023-11-30 |
HRP20231475T1 (hr) | 2024-03-01 |
JP7294681B2 (ja) | 2023-06-20 |
EP3798220A4 (en) | 2022-02-23 |
WO2019223732A1 (zh) | 2019-11-28 |
KR102599761B1 (ko) | 2023-11-08 |
AU2019272383B2 (en) | 2021-09-23 |
US11365181B2 (en) | 2022-06-21 |
CA3101226C (en) | 2023-03-07 |
EP3798220A1 (en) | 2021-03-31 |
RU2762562C1 (ru) | 2021-12-21 |
JP2021525241A (ja) | 2021-09-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2762562C9 (ru) | ПРОИЗВОДНОЕ п-ФЕНИЛЕНДИАМИНА КАК РЕГУЛЯТОР КАЛИЕВЫХ КАНАЛОВ, СПОСОБ ЕГО ПОЛУЧЕНИЯ И МЕДИЦИНСКОГО ПРИМЕНЕНИЯ | |
JP7104746B2 (ja) | 多環式化合物及びその使用方法 | |
CN113767103B (zh) | 新型螺环类K-Ras G12C抑制剂 | |
CN106928206B (zh) | 醛基类化合物及其制法和用途 | |
CN112041296B (zh) | 包含苯并含氧脂肪环结构的氨基乙酰胺类化合物及其用途 | |
CN114456163A (zh) | 四氢吡啶并嘧啶二酮类衍生物、其制备方法及其在医药上的应用 | |
WO2022206706A1 (zh) | 含螺环类衍生物、其制备方法和应用 | |
US20230077155A1 (en) | Tetrahydroisoquinoline compound as potassium channel modulator and preparation and application thereof | |
CN106336406B (zh) | 具有β2受体激动及M受体拮抗活性的八氢并环戊二烯衍生物及其在医药上的用途 | |
RU2800873C1 (ru) | Соединение тетрагидроизохинолина в качестве модулятора калиевых каналов, его получение и применение | |
CA2050587C (en) | Bicyclolactam derivative | |
CN113149894B (zh) | (e)-3-芳杂环基丙-2-烯酸衍生物的制药用途 | |
CN114957296B (zh) | 一类新型阿尔茨海默病检测探针及其生物应用 | |
CN117769545A (zh) | 含三并环类衍生物调节剂、其制备方法和应用 | |
CN117843633A (zh) | 亚砜亚胺类化合物、其药物组合物和用途 | |
TW201706264A (zh) | 吡咯啶-2,5-二酮衍生物之多晶形式、醫藥組合物及用做為吲哚胺2,3-雙加氧酶1(ido1)抑制劑之方法 | |
AU2010242307A1 (en) | Thiophene derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Reissue of patent specification |